Post-COVID-19 Interstitial Lung Disease: Understanding Residual Effects of the Pandemic

Five years after the COVID-19 pandemic, the world continues to grapple with its residual effects, including the emergence of a new entity known as post-COVID-19 interstitial lung disease (PC-ILD). Researchers from Maimonides Medical Center in New York have published a study highlighting the characteristics, mechanisms, and potential therapies for PC-ILD, which has become a concern due to its widespread impact. The study emphasizes the need for continued research to guide decisions and improve outcomes in treatment and follow-up.

Key Takeaways:

• Post-COVID-19 interstitial lung disease (PC-ILD) has emerged as a unique entity with age, male sex, smoking, and the severity of acute illness as risk factors.
• The study discusses possible mechanisms for disease occurrence, including genetic similarities between PC-ILD and idiopathic pulmonary fibrosis.
• Characteristic radiographic findings, pulmonary function abnormalities, and potential therapies are also discussed in the study.
• The researchers highlight the importance of continued research in this field to guide decisions and improve outcomes in treatment and follow-up.
• Maimonides Medical Center is leading the research, with additional authors including Tharun Shyam, Medha Venigalla, and Odai Sinokrot.
• The study's findings emphasize the need for better understanding of the long-term consequences of COVID-19 infection.

Statistics:

• Age is a risk factor for PC-ILD, with older individuals being more susceptible.
• Male sex is also a risk factor, with men being more likely to develop PC-ILD.
• Smoking is a significant risk factor for PC-ILD, with smokers being more likely to develop the condition.
• The severity of acute illness is also a risk factor, with those who experienced severe COVID-19 infection being more likely to develop PC-ILD.

Sources:

• NewsRx. New COVID-19 Data Have Been Reported by Researchers at Maimonides Medical Center (Scars from the pandemic: understanding post-COVID-19 interstitial lung disease). Medical Letter on the CDC & FDA. November 2, 2025; p 81.
• Scars from the pandemic: understanding post-COVID-19 interstitial lung disease. Breathe, 2025;21(4):250037.
• Maimonides Medical Center, Pulmonary and Critical Care Medicine, New York, NY, United States.